Join to view full profile
875 Blake Wilbur Drive Cc2221Stanford Advanced Medicine CenterStanford, CA 94305
Phone+1 650-725-8630
Fax+1 650-498-4686
Dr. Nagpal is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of California (San Francisco)Residency, Internal Medicine, 2006 - 2007
Perelman School of Medicine at the University of PennsylvaniaClass of 2004
Certifications & Licensure
CA State Medical License 2006 - 2027
IA State Medical License 2004 - 2011
American Board of Psychiatry and Neurology Neurology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2012-2014, 2016-2017
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2012-2014, 2016-2017
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013
Clinical Trials
- Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma Start of enrollment: 2016 Aug 01
- BPM31510 in Treating Patients With Recurrent High-Grade Glioma Previously Treated With Bevacizumab Start of enrollment: 2017 Jan 04
- Pivotal, Randomized, Open-label Study of Optune® (Tumor Treating Fields) Concomitant With RT & TMZ for the Treatment of Newly Diagnosed GBM Start of enrollment: 2020 Dec 08
Roles: Principal Investigator, Contact
Publications & Presentations
PubMed
- Phase 2 test of QBS72S for breast cancer leptomeningeal disease.Seema Nagpal, Brandon Carlson-Clarke, Sahara S Rout, Thy T H Trinh, Meaghan Roy-O'Reilly
Neuro-Oncology. 2026-08-07 - Arterial Spin Labeling-Derived Fractional Tumor Burden as a Primary Biomarker for Differentiating Recurrent Tumor from Radiation Necrosis After Stereotactic Radiosurgery.Rafail Christodoulou, Elham Rahimy, Erqi Liu Pollom, Melanie Hayden Gephart, Seema Nagpal
AJNR. American Journal of Neuroradiology. 2026-08-05 - The Interplay of Parental Leave, Career Achievement, and Burnout in Academic Neurologists: A Multicenter Study.Sima Patel, Parneet Grewal, Annie He, Suma Shah, Halley B Alexander
Journal of Women's Health. 2026-07-01
Press Mentions
Vorasidenib for Certain IDH-Mutant Gliomas: Is It Worth It?December 2nd, 2024- BPGbio to Present New Data on Novel Glioblastoma Therapies at SNO 2024November 21st, 2024
- How COVID-19 Could Be Contributing to More Diabetes DiagnosesFebruary 9th, 2022
Professional Memberships
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
